Status:

COMPLETED

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Lead Sponsor:

Eli Lilly and Company

Conditions:

Postmenopausal Osteoporosis

Eligibility:

FEMALE

50+ years

Phase:

PHASE4

Brief Summary

Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.

Eligibility Criteria

Inclusion

  • Postmenopausal women aged at least 50 years
  • A previous clinical diagnosis of osteoporosis
  • At high risk for fracture
  • Current therapy for at least 18 months prior to study entry with either raloxifene HCl or alendronate Na

Exclusion

  • History of metabolic bone disease other than osteoporosis
  • History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma

Key Trial Info

Start Date :

November 1 2004

Trial Type :

INTERVENTIONAL

End Date :

May 1 2007

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT00079924

Start Date

November 1 2004

End Date

May 1 2007

Last Update

May 25 2007

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Birmingham, Alabama, United States

2

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Huntsville, Alabama, United States

3

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Scottsdale, Arizona, United States

4

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Jacksonville, Florida, United States